The total number record retrieved from this search are 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
OV_4087	Vaccinia virus	VVstrain LIVP 6.1.1	DNA	Poxviridae	Mutant for J2R gene	Yes	No	No	University of colorado, USA	Human canine soft tissue sarcoma	STSA-1	NA	NA	MTT assay	0.1 MOI	100% cell survival after 24 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4088	Vaccinia virus	VVstrain LIVP 6.1.1	DNA	Poxviridae	Mutant for J2R gene	Yes	No	No	University of veterinary medicine, germany	Human mammary carcinoma cell line	MTH52c	NA	NA	MTT assay	0.1 MOI	50% cell survival after 48 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4089	Vaccinia virus	VVstrain LIVP 6.1.1	DNA	Poxviridae	Mutant for J2R gene	Yes	No	No	University of veterinary medicine, germany	Human mammary adenoma cell line	ZMTH3	NA	NA	MTT assay	0.1 MOI	30% cell survival after 48 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4090	Vaccinia virus	VVstrain LIVP 6.1.1	DNA	Poxviridae	Mutant for J2R gene	Yes	No	No	University of veterinary medicine, germany	Human prostate carcinoma cell line	CT1258	NA	NA	MTT assay	0.1 MOI	40% cell survival after 48 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4091	Vaccinia virus	VVstrain LIVP 6.1.1	DNA	Poxviridae	Mutant for J2R gene	Yes	No	No	University of colorado, USA	Human canine soft tissue sarcoma	STSA-1	NA	NA	MTT assay	0.1 MOI	60% cell survival after 48 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4092	Vaccinia virus	VVstrain LIVP 6.1.1	DNA	Poxviridae	Mutant for J2R gene	Yes	No	No	University of veterinary medicine, germany	Human mammary carcinoma cell line	MTH52c	NA	NA	MTT assay	0.1 MOI	25% cell survival after 72 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4093	Vaccinia virus	VVstrain LIVP 6.1.1	DNA	Poxviridae	Mutant for J2R gene	Yes	No	No	University of veterinary medicine, germany	Human mammary adenoma cell line	ZMTH3	NA	NA	MTT assay	0.1 MOI	10% cell survival after 72 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4094	Vaccinia virus	VVstrain LIVP 6.1.1	DNA	Poxviridae	Mutant for J2R gene	Yes	No	No	University of veterinary medicine, germany	Human prostate carcinoma cell line	CT1258	NA	NA	MTT assay	0.1 MOI	10% cell survival after 72 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4095	Vaccinia virus	VVstrain LIVP 6.1.1	DNA	Poxviridae	Mutant for J2R gene	Yes	No	No	University of colorado, USA	Human canine soft tissue sarcoma	STSA-1	NA	NA	MTT assay	0.1 MOI	40% cell survival after 72 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4096	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of veterinary medicine, germany	Human mammary carcinoma cell line	MTH52c	NA	NA	MTT assay	0.1 MOI	95% cell survival after 24 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4097	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of veterinary medicine, germany	Human mammary adenoma cell line	ZMTH3	NA	NA	MTT assay	0.1 MOI	95% cell survival after 24 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4098	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of veterinary medicine, germany	Human prostate carcinoma cell line	CT1258	NA	NA	MTT assay	0.1 MOI	95% cell survival after 24 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4099	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of colorado, USA	Human canine soft tissue sarcoma	STSA-1	NA	NA	MTT assay	0.1 MOI	95% cell survival after 24 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4100	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of veterinary medicine, germany	Human mammary carcinoma cell line	MTH52c	NA	NA	MTT assay	0.1 MOI	60% cell survival after 48 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4101	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of veterinary medicine, germany	Human mammary adenoma cell line	ZMTH3	NA	NA	MTT assay	0.1 MOI	30% cell survival after 48 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4102	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of veterinary medicine, germany	Human prostate carcinoma cell line	CT1258	NA	NA	MTT assay	0.1 MOI	50% cell survival after 48 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4103	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of colorado, USA	Human canine soft tissue sarcoma	STSA-1	NA	NA	MTT assay	0.1 MOI	60% cell survival after 48 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4104	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of veterinary medicine, germany	Human mammary carcinoma cell line	MTH52c	NA	NA	MTT assay	0.1 MOI	20% cell survival after 72 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4105	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of veterinary medicine, germany	Human mammary adenoma cell line	ZMTH3	NA	NA	MTT assay	0.1 MOI	25% cell survival after 72 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4106	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of veterinary medicine, germany	Human prostate carcinoma cell line	CT1258	NA	NA	MTT assay	0.1 MOI	10% cell survival after 72 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4107	Vaccinia virus	VVstrain GLV-5b451	DNA	Poxviridae	Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Yes	No	No	University of colorado, USA	Human canine soft tissue sarcoma	STSA-1	NA	NA	MTT assay	0.1 MOI	50% cell survival after 72 hours	No	No	NA	No response	NA	NA	NA	NA	26205404
OV_4110	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human colon carcinoma cell line	Caco-2	1.0E+5 cells per well	NA	MTT assay	0.1 MOI	80% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4111	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human lung cancer cell line	A549	1.0E+5 cells per well	NA	MTT assay	0.1 MOI	90% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4112	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human osteosarcoma cell line	U2OS	1.0E+5 cells per well	NA	MTT assay	0.1 MOI	95% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4113	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human fibroblast cell line BJ	BJ	1.0E+5 cells per well	NA	MTT assay	0.1 MOI	95% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4114	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human colon carcinoma cell line	Caco-2	1.0E+5 cells per well	NA	MTT assay	1 MOI	40% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4115	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human lung cancer cell line	Caco-2	1.0E+5 cells per well	NA	MTT assay	1 MOI	50% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4116	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human osteosarcoma cell line	U2OS	1.0E+5 cells per well	NA	MTT assay	1 MOI	90% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4117	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human fibroblast cell line	BJ	1.0E+5 cells per well	NA	MTT assay	1 MOI	95% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4118	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human colon carcinoma cell line	Caco-2	1.0E+5 cells per well	NA	MTT assay	10 MOI	10% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4119	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human lung cancer cell line	Caco-2	1.0E+5 cells per well	NA	MTT assay	10 MOI	20% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4120	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human osteosarcoma cell line	U2OS	1.0E+5 cells per well	NA	MTT assay	10 MOI	90% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4121	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human fibroblast cell line	BJ	1.0E+5 cells per well	NA	MTT assay	10 MOI	90% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4122	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human colon carcinoma cell line	Caco-2	1.0E+5 cells per well	NA	MTT assay	100 MOI	5% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4123	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human lung cancer cell line	Caco-2	1.0E+5 cells per well	NA	MTT assay	100 MOI	30% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4124	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human osteosarcoma cell line	U2OS	1.0E+5 cells per well	NA	MTT assay	100 MOI	95% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4125	Adenovirus	Ad-CCL20-CD40L	DNA	Adenoviridae	Addition of CCL20 and CD40L gene near by TERT promoter	Yes	No	virus expressing CCL20 chemokine gene	ATCC	Human fibroblast cell line	BJ	1.0E+5 cells per well	NA	MTT assay	100 MOI	95% cell survival after 7 days	No	No	NA	No response	NA	NA	NA	NA	26208317
OV_4126	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (0.01 ng/ml)	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	100 vp/cell	80% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4127	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (1 ng/ml)	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	1000 vp/cell	50% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4128	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (10 ng/ml)	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	10000 vp/cell	20% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4129	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (100 ng/ml)	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	100000 vp/cell	100% cell killing	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4130	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (1000 ng/ml)	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	1000000 vp/cell	100% cell killing	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4131	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	100 vp/cell	100% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4132	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	1000 vp/cell	85% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4133	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	10000 vp/cell	35% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4134	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	100000 vp/cell	20% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4135	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	BxPC-3	3.0E+3 cells per well	NA	MTT assay	1000000 vp/cell	100% cell killing	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4136	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (1000 ng/ml)	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	1 vp/cell	100% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4137	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (10000 ng/ml)	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	10 vp/cell	100% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4138	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (100000 ng/ml)	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	100 vp/cell	70% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4139	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (1000000 ng/ml)	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	1000 vp/cell	20% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4140	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (10000000 ng/ml)	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	10000 vp/cell	100% cancer cell killing	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4141	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	No	Virus in combination with drug Gemcitabine (100000000 ng/ml)	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	100000 vp/cell	100% cancer cell killing	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4142	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	1 vp/cell	100% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4143	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	10 vp/cell	100% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4144	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	100 vp/cell	100% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4145	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	1000 vp/cell	40% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4146	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	10000 vp/cell	10% cell survival	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4147	Adenovirus	AduPARE1A	DNA	Adenoviridae	Addition of E1A gene upstream of uPAR promoter	Yes	No	No	ATCC	Human pancreatic cancer cell line	PANC-1	3.0E+3 cells per well	NA	MTT assay	100000 vp/cell	100% cancer cell killing	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	NA	NA	26227809
OV_4150	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4151	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	60% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4152	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	60% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4153	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	25% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4154	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	10% cell viability after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4155	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4156	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	40% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4157	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	30% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4158	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4159	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4160	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4161	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	60% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4162	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	50% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4163	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	5% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4164	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4165	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4166	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	20% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4167	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	15% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4168	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	2% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4169	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4170	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4171	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	90% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4172	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	70% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4173	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	40% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4174	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	30% cell viability after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4175	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4176	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	50% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4177	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	20% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4178	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4179	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4180	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4181	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	80% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4182	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	58% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4183	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	20% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4184	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4185	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4186	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	50% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4187	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4188	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell killing after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4189	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4275	Alphavirus	M1	RNA	Togaviridae	None	Yes	No	No	SICB	Human melanoma cell line	B16	4000 cells per well	NA	MTT assay	10 pfu	2.19 % cell viability after 72 hours	No	No	NA	No response	NA	Activation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	NA	NA	26373347